Abstract library

2061 results for "tumor site (peripheric versus central)".
#3032 Lung Side and Site: The Importance of Location and the Prognostic Implication in Lung Neuroendocrine Tumors
Introduction: Lung neuroendocrine tumors (NET) are classified as typical (TC) and atypical carcinoids (AT), according to their mitotic count and the presence of necrosis. However, a role for tumor side (right vs left) and location (central vs peripheric) has not been established so far.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: MD Anna La Salvia
#795 Efficacy of Octreotide LAR (OCT) in Patients (pts) with Advanced Neuroendocrine Tumors (NET): A Subgroup Analysis of Phase III RADIANT-2 Study with Updated Overall Survival (OS)
Introduction: OCT has shown antitumor activity and significantly prolonged time to tumor progression vs PBO in pts with metastatic midgut NET (PROMID).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Jonathan R Strosberg
#1285 Gastrointestinal Neuroendocrine Tumors of Unknown Primary Site: Report from a Series at a Single Institute
Introduction: Neuroendocrine neoplasms of unknown primary (NENs-UP) account for 10-13% of all NENs and show different biologic behavior, histologic appearance and clinical outcome.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: dr Sara Massironi
#162 Different sites of rare metastases in neuroendocrine tumor patients detected by Ga-68 somatostatin receptor PET/CT
Introduction: The most common sites of metastases in neuroendocrine tumors are liver, lymph nodes, and bone.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Baum R P, ...
#633 Clinical and Prognostic Features of Neuroendocrine Tumor of Unknown Primary Site
Introduction: Neuroendocrine tumors of unknown primary site (NET UPS) are rare and heterogenous tumors with poor prognosis. There is little information available on the treatment and prognosis.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Surgical treatment
Presenting Author: M.D., Ph.D. Hyun-Jeong Shim
Authors: Shim H J, Kim D, Hwang J E, Lee K H, ...
#57 Clinical and demographic characteristics in patients newly diagnosed with neuroendocrine tumors (NET)
Introduction: Neuroendocrine tumors (NETs) are tumors that form from cells that release hormones in response to a signal from the nervous system. These tumors may secrete higher-than-normal amounts of hormones, which can cause many different symptoms.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Chi-Chang Chen
#144 Oxaliplatin-based chemotherapy in patients with advanced neuroendocrine carcinoma: an Italian retrospective multicenter analysis
Introduction: Conventional chemotherapy does not have a well-defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs). Various regimens were evaluated. Cisplatin or carboplatin combined with etoposide are usually indicated in poorly differentiated (PD) NECs. Some evidence exists for oxaliplatin activity in WD and PD NECs, combined with capecitabine or gemcitabine.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Francesca Spada
#1828 5-Fluorouracile Plus Dacarbazine in Metastatic Digestive Neuroendoendocrine Tumors: Efficacy and Potential Biomarkers
Introduction: The 5-fluorouracile (5FU) + dacarbazine (DTIC) combination has been poorly evaluated in NET
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Dr Louis de Mestier
#902 Chemotherapy for Advanced Neuroendocrine Tumors (NETs): Patient Selection Should be Independent of Primary Tumor Site
Introduction: Chemotherapy (CT) is used to treat patients (pts) with advanced poorly-differentiated (Pd); or well-differentiated (Wd) NETs with high-tumor burden (usually of pancreatic (pNET) origin).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Angela Lamarca
#2786 Outcome of NET Liver Metastases Treated by TAE Using Microspheres
Introduction: Liver metastases are common in patients with neuroendocrine tumors (NETs), which are associated with the prognosis. Transarterial embolization (TAE) is one of the options for selective therapy in patients with multiple unresectable progressive liver metastases after chemotherapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Xiaoliang Chen
Authors: Chen X, Hu L, ...